Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 15, 2021

Noxxon Pharma secures DSMB approval to continue brain cancer study

Noxxon Pharma has secured a positive recommendation from the Data Safety Monitoring Board (DSMB) to continue recruiting patients for the NOX-A12 plus radiotherapy brain cancer study.

Noxxon Pharma has secured a positive recommendation from the Data Safety Monitoring Board (DSMB) to continue recruiting patients for the NOX-A12 plus radiotherapy brain cancer study.

The independent body concluded that it is safe to continue with the enrolment after assessing safety data from the initial four weeks of treatment of the first patient recruited in the third and final dose cohort of the study.

The Phase I/II clinical study involves testing three dose regimens of NOX-A12 (200mg, 400mg and 600mg/week) along with external-beam radiotherapy in newly diagnosed brain cancer patients.

The participating clinical centres have now started final patient recruitment for the last and highest dose group. Once all patients in the third cohort have received four weeks of treatment, DSMB will again assess safety and tolerability.

The meeting will subsequently determine the recommended dose for the next randomised, controlled brain cancer trial.

Noxxon CEO Aram Mangasarian said: “We are pleased by the safety data confirmation of the DSMB, as it will allow our study to progress and the last patients to receive treatment at the highest planned dose of NOX-A12.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“This achievement brings us one step closer to a topline data readout for this cohort sometime around the end of Q3 2021. As the study advances, we will be analysing data which will be used to define the recommended dose and guide preparations for a potentially registrational Phase II study.

“The recent capital raise plus available financing vehicles secure Noxxon’s financial runway well into 2022, thereby allowing us to address operational matters crucial for the future of the company.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU